Inclusion Criteria:  Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening biopsy, blood sample, faeces and questionnaires 18 years old at time of written consent Patient with histologically confirmed lung cancer Lung cancer metastatic disease or locally advanced not eligible for local curative treatment intent Patient with metastases that can be biopsied. Performance status ≤ 2 (according to WHO criteria) At least one measurable target on CT scan according to RECIST 1.1 Indication of any systemic therapeutic strategy can be performed alongside this current cohort in accordance with national and / or international recommendations. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. Patient must be affiliated to a Social Health Insurance  Exclusion Criteria:  Other malignancy treated within the last 3 years (except non-melanoma skin cancer or in situ carcinoma of the cervix) Other neuroendocrine tumour than small cell or large cell carcinoma. Coagulopathy or other pathology that contraindicates biopsy procedures Pregnant or nursing patient Individual deprived of liberty or placed under the authority of a tutor Impossibility to submit to the medical follow-up of this clinical trial for geographical, social or psychological reasons